Summary & Overview
Cardiac Defibrillator Implant with Cardiac Catheterization and MCC: Inpatient Reimbursement Overview
DRG 275 describes inpatient hospitalizations for cardiac defibrillator implantation combined with cardiac catheterization when a Major Complication or Comorbidity is present. This grouping is clinically significant because the added severity drives higher Medicare Severity Diagnosis-Related Group reimbursement to account for increased resource use and complexity of care.
DRG 275 Overview
DRG 275 covers inpatient cases involving implantation of a cardiac defibrillator with concurrent cardiac catheterization where a Major Complication or Comorbidity is present. Typical clinical scenarios include device placement for arrhythmia management performed during or immediately following diagnostic or therapeutic catheterization, with significant comorbid conditions that increase resource use. This Diagnosis-Related Group is important for Medicare payment because the presence of a Major Complication or Comorbidity elevates the reimbursement relative to lower-severity groups, reflecting higher expected hospital costs and length of stay. Accurate coding of procedures and comorbidities directly affects inpatient revenue under Medicare Severity Diagnosis-Related Group-based payment.
Clinical Trials
- Acute procedural optimization studies: Research assessing intra-procedural strategies during combined cardiac defibrillator implantation and cardiac catheterization, such as optimal timing/sequencing of lead placement relative to coronary interventions, anesthesia approaches, or periprocedural anticoagulation management. These trials enroll patients undergoing concomitant device implantation and catheter-based coronary assessment or intervention, often high-risk individuals with advanced heart failure or recent ischemic events. Findings are relevant to providers and payers because procedural protocols that reduce complications, procedure time, or length of stay can improve clinical outcomes and lower inpatient costs for this high-acuity DRG.
- Comparative effectiveness trials of device and technique selection: Studies comparing different implantable defibrillator systems (single- vs. dual-lead, subcutaneous vs. transvenous where applicable), lead fixation methods, or post-implant programming strategies in patients who also require cardiac catheterization for ischemic disease. These trials focus on subgroups such as patients with significant coronary artery disease, reduced ejection fraction, or multiple comorbidities to determine which device/technique combinations yield fewer major complications, readmissions, or reinterventions. Results inform clinical decision-making and reimbursement policy by identifying higher-value device strategies for a population that drives substantial inpatient resource use.
- Post-discharge outcomes and care-pathway research: Observational cohorts and pragmatic trials evaluating transitions of care, remote monitoring, and structured rehabilitation in the weeks to months after hospital discharge for patients who had a defibrillator implanted and underwent catheterization. These studies examine rates of device-related complications, heart failure readmissions, adherence to guideline-directed medical therapy, and the impact of remote device interrogation or coordinated heart-failure clinics on downstream utilization. For payers and hospital administrators, evidence from this research can guide investment in follow-up programs that reduce readmissions and total cost of care for patients within this DRG.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.